

1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

Product Name: Hypaque® Meglumine

Synonyms: Hypaque® Meglumine 30%
Hypaque® Meglumine 60%

Applications: Radiodiagnostic

Emergency Number: In an emergency, call 1-800-654-0118

Manufacturer: Amersham Health
101 Carnegie Center
Princeton, NJ 08540-9998
609-514-6000 or 1-800-654-0118

2. COMPOSITION/INFORMATION ON INGREDIENTS

<u>Ingredient</u>	<u>CAS No.</u>	<u>Percent by Weight</u>
Diatrizoic Acid Dihydrate	7732-18-5	10.0 to 25.0
Water		> 25.0
Meglumine		5.0 to 25.0

3. HAZARDS IDENTIFICATION

*****EMERGENCY OVERVIEW*****

A colorless to pale yellow aqueous solution. Presents little or no hazard if spilled or in a fire.

WARNING: This is a pharmaceutical material available only with a prescription - use only as directed. Overdose, may cause adverse cardiovascular, gastrointestinal, nervous, respiratory and urogenital system effects.

4. FIRST AID MEASURES

Eyes: In case of eye contact, flush eyes with plenty of water for at least 15 minutes.
Seek medical attention if irritation develops.

Skin: Wash thoroughly with soap and water.

Ingestion: Seek immediate medical attention or contact the Poison Control Center for further instructions.

Inhalation: Not an expected route of entry.

5. FIRE FIGHTING MEASURES

Flammable Properties: Nonflammable. This is an aqueous-based formulation.

Extinguishing Media: Use any extinguishing agent which is suitable for the surrounding fire.

Fire Fighting Procedures: Use normal fire fighting gear. May release irritating iodine vapors when exposed to fire conditions.

Unusual Fire and Explosion Hazards: None known

6. ACCIDENTAL RELEASE MEASURES

Spills: Contain the spill by placing paper towels or a suitable absorbent material around the edges of the spill and work inward. Carefully scoop up into a properly labeled waste container for disposal. Wash area of spill to remove from surfaces.

7. HANDLING AND STORAGE

Handling and Storage

Precautions: Keep this and all drugs out of the reach of children.

Work/Hygienic

Practices: Use good personal hygiene - wash hands and exposed skin thoroughly with soap and water after use.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Engineering Controls: Normal ventilation

Eye/Face Protection: None normally required. Avoid eye contact.

Skin Protection: None normally required.

Respiratory Protection: None normally required.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance: Clear liquid

Color: Colorless to pale yellow

Solubility in Water: Soluble

Specific Gravity: Not applicable

10. STABILITY AND REACTIVITY

Stability: Stable

Conditions to Avoid: Exposure to flame or temperature above 300°F may produce iodine vapors.

Materials to Avoid: None known

**Hazardous
Decomposition**

Products: Iodine vapors

Hazardous

Polymerization: Will not occur

11. TOXICOLOGICAL INFORMATION

Subchronic (Target Organ Effects): The following adverse reactions have been reported:

- **Cardiovascular System:** Vasodilation.
- **Digestive System:** Nausea, vomiting.
- **Nervous System:** Paresthesia, dizziness.
- **Respiratory System:** Rhinitis, increased cough.
- **Skin and Appendages:** Urticaria, pain at the injection site, painful hot erythematous swelling above the venipuncture site.
- **Special Senses:** Perversion of taste.
- **Urogenital System:** Osmotic nephrosis of the proximal tubular cells.
- **Clinical signs of systemic intolerance:** Tremors, irritability, tachycardia, dyspnea and pulmonary edema.

Carcinogenicity: TP: No, IARC: No, OSHA: No

12. ECOLOGICAL INFORMATION

No data available

13. DISPOSAL CONSIDERATIONS

Dispose in accordance with local, state and federal regulations.

14. TRANSPORT INFORMATION

Proper Shipping Name: Non-regulated

15. REGULATORY INFORMATION

U.S. Federal Regulations:

Federal law prohibits dispensing without prescription. This product does **not** contain any ingredients which are regulated on the U.S. EPA List of Toxic Chemicals (40 CFR 372), and is therefore not subject to release reporting under Section 313 of EPCRA.

16. OTHER INFORMATION

Revision Date: April 2003 (company name and emergency number)

Reference

Documentation: Primary references used in the preparation of this document.

1. [Hypaque® Meglumine] Package Insert
2. [Hypaque® Meglumine] MSDS (Sterling Winthrop)
3. ACGIH Guide to Occupational Exposure Values - 1991
4. Sterling Winthrop Corporate Quality Pharmaceutical File - 2/10/89

Disclaimer:

This information is furnished without warranty, representation, or license of any kind, except that it is accurate to the best of Amersham Health. knowledge or obtained from sources believed to be accurate. Amersham Health. does not assume any legal responsibility for use or reliance upon same. Customers are encouraged to conduct their own tests. Before using any product, read its label.